Beyond Air Q1 2026 Earnings Call Transcript

Quartr
Provided by Quartr
August 12, 2025

Key Takeaways

  • Positive Sentiment: Revenue for Q1 FY26 rose 157% year-over-year to $1.8 M and 50% sequentially, reflecting strong market adoption of LungFit PH.
  • Positive Sentiment: Operating expenses were cut by 40% year-over-year to $7.5 M, helping reduce net cash burn by over 60% compared with Q1 last year.
  • Positive Sentiment: Beyond Air reaffirmed its FY26 revenue guidance of $12 M–$16 M, highlighting confidence in its sales pipeline and commercial strategy.
  • Positive Sentiment: International revenues were recorded for the first time in Q1, with distribution partnerships now in 30+ countries covering over 2 billion lives globally.
  • Neutral Sentiment: The company is focused on securing FDA clearance for its second-generation LungFit PH2 device in 2026, but timing and outcomes remain subject to regulatory review.
AI Generated. May Contain Errors.
Earnings Conference Call
Beyond Air Q1 2026
00:00 / 00:00

There are 8 speakers on the call.

Operator

Good afternoon, and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter Ended 06/30/2025. At this time, participants are in a listen only mode. A question and answer session will follow the formal presentation. And now, I would like to turn the call over to Corey Davis from LifeSci Advisors. Please go ahead.

Speaker 1

Thank you, operator. Good afternoon, everyone, and thank you for joining us. Today, after the market closed, we issued a press release announcing the operational highlights and financial results for Beyond Air's 2026 ended 06/30/2025. A copy of this press release can be found on our website at www.beyondair.net under the News and Events section. Before we begin, I would like to remind everyone that we will be making comments and various remarks about future expectations, plans and prospects, which constitute forward looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.

Speaker 1

Beyond Air cautions that these forward looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. We encourage everyone to review the company's filings with the Securities and Exchange Commission, including, without limitation, the company's most recent Form 10 ks and Form 10 Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward looking statements. Additionally, this conference call is being recorded and will be available for audio rebroadcast on our website, beyondair.net. Furthermore, the content of this conference call contains time sensitive information that is accurate only as of the date of the live broadcast, 08/12/2025. Beyond Air undertakes no obligation to revise or update any statement to reflect events or circumstances after the date of this call.

Speaker 1

With that, I'll turn the call over to Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. Go ahead, Steve.

Speaker 2

Thanks, Corey, and good afternoon to everyone. With me here today is Doug Larson, our Chief Financial Officer. I will be brief today, given the update just seven weeks ago on our fiscal earnings call. We continue to drive strong market adoption of LungFit PH, which was reflected in our financial results for the first fiscal quarter, including a 157% increase in revenue to 1,800,000.0 compared with $700,000 for the same period last year. On a sequential basis, we reported a 50% increase over the quarter ended 03/31/2025.

Speaker 2

As a reminder, it was only a year ago that we implemented broad changes to our sales team and strategy under the leadership of the new Chief Commercial Officer, David Webster. This strategy included building out our distribution network in The United States and internationally, focusing more heavily on fostering customer relationships. While we quickly reported seeing positive market reactions to the new strategy and team, and our backlog of agreements started to build, it's only been over the course of the last two quarters that the financial performance of the company has really caught up. That said, our sales pipeline continues to build, and the more customers use LungFit PH, the more confidence grows in the product and our ability to provide top tier service. The key takeaway here is that we are now well positioned to overcome the barriers to entry in the nitric oxide market with LungFit PH, and are well on our way to becoming the market leader with the addition of LungFit PH2 in calendar year 2026, pending regulatory clearance.

Speaker 2

Considering the strong momentum in our business, we are reaffirming our revenue guidance of 12,000,000 to $16,000,000 for fiscal year twenty twenty six. I will dig a little deeper into the specific drivers behind our financial performance in the 2026, and for the future. We continue to generate a steady flow of new hospital contracts in The U. S. With two new hospital starts and contract renewals with three hospitals.

Speaker 2

Some other important points I would like to put out there. One, more than 55% of our contracts are multi year contracts. Two, this was the first quarter of international revenues being recorded. This comes after a tremendous amount of time spent working with our partners around the world, which we have documented on previous calls and in press releases. To put our current reach into perspective, we now have access to over 30 countries, distribution partners covering more than 2,000,000,000 lives.

Speaker 2

We expect growth each quarter going forward with momentum picking up substantially in fiscal twenty twenty seven. Turning back to The U. S, one of the market barriers we have focused on overcoming are the hospital networks and national purchasing groups. We've just been added to the Premier Network, which gives us two of the big three, as we were added to Visian two years ago. Combined, these two GPUs provide us with access to close to 3,000 hospitals.

Speaker 2

We still have to be highly selective in our targeting, until we have the second generation LungFit system, which is smaller, lighter, and designed for air and ground transportation, while still delivering all the revolutionary features of the first generation machine. We believe that this system will offer capabilities that will allow us to penetrate larger hospitals and larger hospital systems. Overall, we anticipate FDA approval of the second generation system and subsequent introduction to The U. S. Market will have a major impact on our market share, total annual volume and logistics within the hospital.

Speaker 2

In regard to the Premier contract, we were awarded a national group purchasing agreement for therapeutic gases. This new agreement allows Premier members at their discretion to take advantage of special pricing in terms pre negotiated by Premier for the LungFit PH system, and disposable NO2 smart filters. This is a significant network for us to be aligned with, and we believe it will open a lot of doors for our sales team. Having this purchasing agreement will help streamline the sales process for Premier Hospital network members, as they contemplate converting their No supply to LungFit PH. Turning to Beyond Cancer, we are assessing the best path forward for the program at this time.

Speaker 2

Phase 1b combination study with anti PD-one therapy is the target, and we will communicate more details once we secure a clinical trial site. With respect to Neuronos, our subsidiary focused on therapies for autism spectrum disorders, I have no further update from the last time we spoke. As a reminder, Neuronos will meet with FDA later this year regarding its path to human studies, which we expect to begin by the 2026. Our LungFit Go program is still on track for a pre IDE submission to FDA prior to year end to discuss the clinical path forward. We continue to be encouraged by the progress across our business.

Speaker 2

LungFit PH is quickly gaining attention in hospitals across The U. S. And now the world. We look forward to continuing to take market share and build awareness for our system throughout the remainder of fiscal twenty twenty six. And looking out to fiscal twenty twenty seven, we see the introduction of LungFit PH2, putting us on a path to take the majority of market share over time, in what we believe could ultimately be a $1,000,000,000 global NO market.

Speaker 2

Now, I will turn it over to our CFO, Doug Larsen.

Speaker 3

Thanks, Steve, and good afternoon, everyone. Our financial results for the 2026, which ended 06/30/2025 are as follows. Revenue for the fiscal quarter ended 06/30/2025 increased 157% to $1,800,000 compared with $700,000 for the fiscal quarter ended 06/30/2024. We are showing a gross profit increase of approximately $500,000 to $200,000 for the 2026, compared to a loss of $300,000 for the same period last year. The gross profit increase was due to increasing revenues, partially offset by depreciation of additional LungFit devices.

Speaker 3

Turning to operating expenses, I just want to remind everyone that as we've talked about on previous quarterly calls, our team has been laser focused on cost reduction in SG and A, R and D and our supply chain. Over the 2025, we reduced total operating expenses to just above $7,500,000 in the June from $13,000,000 for the same period last year. This translates to a 40% reduction year over year and greater than 55% reduction from a high of $17,000,000 at its peak. We believe a trough in our operating expenses will be in the current quarter, which ends 09/30/2025. Please do not interpret that expenses will be moving up significantly in the December.

Speaker 3

We anticipate expenses will move up in proportion to our commercial performance to maintain our excellence in service and take advantage of coming opportunities. Research and development expenses were $3,100,000 for the fiscal quarter in 2026, as compared with $6,000,000 for the same period last year. The decrease of $2,900,000 was across the board, with decreases in salaries, stock based compensation costs, clinical and preclinical expenses, professional fees, and Gen two device development costs. SG and A expense for the quarters ended 06/30/2025 and 06/30/2024 were $4,700,000 and $7,200,000 respectively. The decrease of $2,500,000 was attributed primarily to the reduction in salaries, stock based compensation costs, marketing and advertising, and legal fees.

Speaker 3

Other expense was $500,000 compared with a $500,000 income for the same period a year ago. The increase in expense of $1,000,000 was mainly due to a prior period gain associated with the change in fair value of the derivative liability for $1,000,000 Net loss attributed to the common stockholders of Beyond Air Inc. Was $7,700,000 or a loss of $1.53 per share basic and diluted. Our net loss for the fiscal quarter ended 06/30/2024 was $12,200,000 or a loss of $5.32 per share basic and diluted. Please note that the per share results were calculated to reflect the company's one for 20 reverse stock split, which became effective on 07/14/2025.

Speaker 3

As a reminder, we implemented this reverse stock split to regain compliance with NASDAQ listing ruling 5550A2. I am pleased to announce that NASDAQ has since notified the company that we are now back in compliance with all listing rules. Net cash burn for the quarter was $4,700,000 which is more than 60% lower than the first quarter of last fiscal year. This decrease reflects our reduction in operating expenses, including wrapping up spending on the development of our next generation LungFit device in the June. We've reported a strong reduction in our cash burn in Q1 and expect to see continued drop again in Q2.

Speaker 3

As of 06/30/2025, we reported cash, cash equivalents and marketable securities of $6,500,000 We believe that our cash and existing financing vehicles will be sufficient to allow us to support current operating plans well into calendar twenty twenty six and potentially to profitability, provided we continue to hit our internal revenue estimates and control costs at Beyond Air. And with that, I'll hand the call back to Steve.

Speaker 2

Thanks, Doug. We'll now take some questions.

Operator

Thank you. Ladies and gentlemen, we will now begin the question and answer session. A confirmation tone will indicate your line is in the question queue. You may press star and 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys.

Operator

The first question comes from the line of Marie Thibault from BTIG. Please go ahead.

Speaker 4

Hi, good evening and congrats on a nice quarter. I wanted to ask kind of a big picture question here. I know you're confident in your guidance range for the year and you had some very nice 50% sequential growth this quarter, so really great to see it. How should we think about the various growth drivers coming together this year, Steve? I'm thinking about existing contracts, things like the Premier agreement.

Speaker 4

Is this all sort of coming together now, or do we need to see new sources of growth, more acceleration in order for you to kind of hit that range? How are you thinking about it?

Speaker 2

Thanks, Marie. Look, you know, we certainly need a little bit more, you know, throughout the next, you know, seven months of the fiscal year. So yeah, we don't have the range set by what was in our pocket today. That's by design, obviously. I mean, we have a lot of open opportunities that are in front of us that we expect to win a certain percentage of those and hit our numbers.

Speaker 2

And we feel very confident about that. So Premier is a big piece of that. I don't think that Premier coming on in July is going to have a major impact on this fiscal year. It does take time. You know, we it takes we've said in the past about four to twelve months from the first contact with the hospital.

Speaker 2

And now with Premier, we're able to have these conversations with their members. Prior to this, we may have had conversations, but really they were just introductory. There really weren't much serious discussions until we got on with Premier. So those discussions are happening now. So we think there could be some impact in this fiscal year.

Speaker 2

But obviously, it'll be a much bigger impact next fiscal year. So what we have in hand is very strong, we're very confident that we'll hit the range. But you know, I think it's unfair to say that Doug and I are sitting here with 12 to 16 in our pocket if nothing else happened from today. That's just not the truth. I don't think it needs to be the truth, Marie.

Speaker 2

I mean, we have a lot of time before the end of the fiscal year.

Speaker 4

Sure, sure. Makes sense. Okay. But you feel good with being on track here. Okay.

Speaker 4

And then I guess I would ask a little bit about OUS. You called out some acceleration, I think in the press release, and I know through your partners you have exposure to several countries. Are there certain countries we should be listening for? Are there opportunities for big tenders here over the coming quarters? I want to get a little smarter on the OUS.

Speaker 2

Yeah, I think, you know, as you mentioned, the tenders, they do take a little bit of time. So, you know, signing up a distributor or distribution partner in a country doesn't mean sales are coming the next day, right? It does take some time. So the initial sales to our distribution partners are through demonstration devices and training devices that they have for themselves. And then a few quarters after that, you'll start to get some victories with hospitals, tenders.

Speaker 2

However they do it in each country will be different. So I think that we would anticipate some of these wins on hospitals coming towards the end of this fiscal year. Getting hospitals signed up in the June or getting partners, excuse me, signed up in the June would put us a couple of quarters later before we start winning hospitals. It does take time. We've to get devices shipped.

Speaker 2

We've got to get everybody trained. We've got to get marketing materials in their hands. So it does take a couple of quarters. So I think that we'll start to see the benefits of what we've put in place as we get towards the end of this fiscal year and into next fiscal year. But the revenues you're seeing now are from us selling to our partners what they need for training and demonstration purposes in their countries.

Speaker 4

Understood. Thanks for the thoughts, Steve.

Speaker 5

Thanks, Marie.

Operator

Thank you. The next question comes from the line of Jason Vitesse from Roth Capital Partners. Please go ahead.

Speaker 5

Hi. Thanks for taking the questions and solid quarter. Just first off, can now that you've kind of revamped the sales effort with the new COO, can you give us a sense of kind of how long it's taking to go from initial contact with the customer to, you know, finally closing a deal and, and sending off the machines?

Speaker 2

Sure. Yeah. I mean, it's it's anywhere from four to twelve months. It does take time from the initial contact. So some are quicker than others, and some have, you know, long process where, you know, they're taking bids from multiple companies, kind of like a tender overseas, a little different here, but those things do exist.

Speaker 2

So it does take time.

Speaker 5

And, I mean, I I I take it you can tell who's gonna take twelve months and who's gonna take four months depending on the hospital system generally, in terms of just your forecasting?

Speaker 2

Usually, we have a pretty good guess. Yeah.

Speaker 5

Okay. Sorry. But just wanted to clarify that.

Operator

Yeah.

Speaker 5

Secondly, if you could help us out on you mentioned that s and g SG and A OpEx expenses are basically going to grow with revenue. Any sense how we should model that? Does that mean mean, from a is that from a percentage basis, a quarterly basis? Or maybe just a little more detail on how we should be thinking about the progression for the rest of the year, assuming we're all going to be modeling kind of within the guidance range you provided?

Speaker 2

Yes, I think like Doug mentioned, you'll see September, you know, tick down from the June. Right now, the December, you know, it might be roughly around the September for expenses, give or take. And, you know, as we start to see the growth, there might be for example, as we get higher sales, there are certain people and certain things we pay commission on. So you'll see expenses tick up. And, I don't think any of our cost cutting offset that as we get towards the end of this fiscal year.

Speaker 2

So you will see some movement. That's why December is kind of shaky on whether it's going to be higher or right around September. But in the March, last quarter of fiscal year, you will see expenses moving up commensurate with the increase in revenues.

Speaker 5

Got it. I'll jump back in queue. Thanks for the detail.

Speaker 2

Thanks.

Operator

Thank you. We take the next question from the line of Justin Walsh from Jones Trading. Please go ahead.

Speaker 6

Hi, thanks for taking the question. You alluded to this, but I was wondering if you could comment on how your engagement efforts are being facilitated by your Premier agreement. I'm just wondering how much of it is a question of getting your foot in the door, raising awareness and removing friction for these hospitals.

Speaker 2

Yeah, I mean, I think just being on with Premier, it removes, you know, the big initial barrier. It's gone. So now we can have free discussions with them. And, you know, one of the nice things about the GPOs is, you know, you set your pricing in the contract with them, so you have something to work off of right away. So it does save a little bit of time.

Speaker 2

So, yeah, I mean, this is a it's a big barrier removed without being on premiere. It's very extremely difficult to contract with a premiere hospital.

Speaker 6

Great. Thanks for taking the question.

Speaker 2

All right. Thank you.

Operator

Thank you. The next question comes from the line of Yale Jen from Laidlaw and Company. Please go ahead.

Speaker 7

Good afternoon, Steve, and congrats on the quarter. My question is that last time in the middle of the quarter, you gave some guidance in terms of the top line. I just wonder whether this time you have any insights or look or can you review anything about all the sales so far in this quarter? And I have a follow-up.

Speaker 2

So yeah, so yeah, last when we reported our fiscal year earnings, I mean, there was like ten days, twelve days left in the quarter. So it wasn't a stretch for us to preannounce that quarter. Now we're not even halfway through the quarter. So I'm not going be commenting on quarterly estimates unless we're again at our fiscal year, which will be next June. So we reiterated our fiscal year guidance, and that should show our confidence.

Speaker 7

Sure. I agree. And that looks good. And do you have any could you give some guidance in terms of how many hospitals at this time already installed Longfit PH?

Speaker 2

I don't think we've given that exact number, but it's getting to be a pretty big number. I mean, guess we could say dozens and dozens of hospitals. So that would be good. I think that's about all I'll But say there, we're certainly growing the hospitals. There's a lot of them using LungFit PH, and the more that do, the more references we get, and the more comfort people have with us as a company servicing them.

Speaker 2

So it's certainly moving in the right direction.

Speaker 7

And maybe squeeze one more here. In terms of the two PMA filing, I know you hate to give guidance because that has sort of unpredictable, but nevertheless just curious what's your current sort of expectation both for the cardiac surgery as well as for the second gen?

Speaker 6

And thanks.

Speaker 2

Yeah, so I'm definitely not going to give timing on this. We're not going to guess what FDA is going to do. But I will say that our focus is on the second generation machine. And as a smaller company, we want to keep FDA focused on what's important to us. And right now, the second generation machine is more important to us than the cardiac indication.

Speaker 2

I think the cardiac indication loses a little bit of its luster with the second generation machine in terms of the impact it will have. So right now, our focus with our team and with FDA, when talking to them, is on Gen two and Gen two only.

Speaker 7

Okay, great. That's very helpful. Again, congrats and appreciate the confidence for the guidance.

Speaker 2

Thanks, Yale.

Operator

Thank you. We take the next question from the line of Jason Bednar from Piper Sandler. Please go ahead.

Speaker 7

Hey, good afternoon.

Speaker 6

Steve, I wanted to start really to try to follow-up on a few questions already. I think a lot of us are really trying to dial in on the guide just in the context of how the year started. The nature of the business here requires these contracts to steadily build throughout the year and really tap into that nice razor razor blade model you have. It seems like you need sequential revenue to grow at 50% quarter over quarter pace in next few quarters to finish near the midpoint of that reaffirmed guide today. I guess beyond that internal confidence you're speaking to, anything more tangible you can give us?

Speaker 6

I know Marie was asking some questions. There have been some others here. Anything beyond just like we're confident we can do this that you can help us bridge that gap on getting to that 50% quarter over quarter growth that we need to see in the business.

Speaker 2

Yeah, I'll do my best. We're now partnered in over 30 countries outside The United States. So all of these partners are going to be working with us and we'll be training them. And we have training sessions in Europe and in The US, so we're moving quickly with our partners. So we anticipate that the revenues from ex US, just to get our partners up and running, is going to be strong throughout the rest of this fiscal year.

Speaker 2

So that we have a lot of confidence in. And we will be signing more partners before the end of this fiscal year. So there's a lot of confidence on the international side from that perspective. And again, Marie had asked about tenders and winning hospitals there. We have very limited amounts of wins in our guidance.

Speaker 2

So if we do get some wins, and I can say that there are some of the partners out there that have already put their hat in the ring for some tenders. It's early days, but they have, in a few countries, so we'll see. So there's definitely some cushion there if we start winning tenders earlier than we expect to. And it's definitely possible, but we're not counting on it, right? This is early days on the international side, so we don't want to make any large assumptions.

Speaker 2

And we haven't in our guidance. Okay, so that's the international side. On the domestic side, you know, we've been at this now for close to three years. We had to change our commercial team. Our chief commercial officer has been here now since thirteen months.

Speaker 2

He's put a lot of things in place. And I think we've already announced a lot of these things, right? We talked about our partnership with Trilamed. They're going to help us with the Department of Defense and the Veterans Administration. We did partner with Guam, you know, at the beginning of this year or end of last year.

Speaker 2

And that was just the beginning. You know, this was something that there was a need, and we stepped up and took care of it. So I think that, you know, the rest of the hospitals and Department of Defense and Veterans Administration are probably going to follow what the normal rules are. And it takes time to get on. Kind of like we got on premiere and busy, it takes time to get on with the Veterans Administration, DOD.

Speaker 2

So we expect that to occur at some point in this fiscal year and contribute. You know, with Premier, we'll have more hospitals. I think we'll get some hospitals there. We've been talking to some before this happens. So I think there'll be some follow through there before the end of the fiscal year.

Speaker 2

Know, David, our new Chief Commercial Officer, has done a very good job with Visient in kind of refocusing our efforts and working with the Visient team so we have a better relationship there. So we see momentum. We see what's in the pipeline for us. So we already have this vision of what's staring us in the face for the next six months. And our machine is performing extremely well.

Speaker 2

You know, when you look back two years ago, we were still waiting for software updates from the FDA. So our incarnation of Gen one at its peak really started in May. So people are getting comfortable with it. You know, we've signed our first luminary site in Vanderbilt. They've been very helpful.

Speaker 2

So I think that there's a lot of momentum for us in The US and internationally so we can get this done. I'm doing my best here. I don't want to give too much information. You know, everyone's listening. We have competitors.

Speaker 2

So I'd like to keep it to what I've said. I hope that satisfies your question.

Speaker 6

Yeah, yeah, if I could follow-up maybe to tease it out just a bit more and feel free to share what you're comfortable with. Can you talk about the attribution you'd give to international out of that 12,000,000 to $16,000,000 and if you're comfortable, the pacing of maybe when you think that some of that might layer in throughout the course of fiscal twenty twenty six? And then point two, you didn't mention it. I don't know if it's possible that you had visibility on contract renewals. You referenced some in your prepared remarks for the first quarter.

Speaker 6

Are economics there superior to what they were previously? Is that contributing? Where are these are expanded relationships or just better economics for Beyond Air that are also embedded in that 12,000,000 to $16,000,000 outlook?

Speaker 2

So in the outlook we don't count on contracts being renewed above where they were before. We don't count on renegotiated contracts. It does happen. I would say that some of our renewals, you know, the hospitals use more than they thought in their first year. And, you know, we will, you know, recontract with them or renew them at higher rates, you know, higher amounts of hours so it is more money.

Speaker 2

So we don't have that in our forecasts. We don't count on that. And Doug's looking at me, you know, like, you know, we definitely have a couple of our customers that are asking us to give them longer term contracts because they're using too much and, you know, they want to make sure that they have certainty of payments, right? So they want to pay the same price every month and they get to month eight or nine and they've used up all the hours that they're supposed to have. So we we will work with them and, and try to come up a way to to make it easier on them.

Speaker 2

But again, we're not we don't have penalties. We don't have extra costs at the end of a contract. They just kind of keep paying at this roughly the same hourly rate that they were paying at for their year. They just have to keep paying that rate if they're using more hours. And sometimes for hospitals it's difficult because they want to just keep the same payment every month.

Speaker 2

So we do have this happen every month or two. There's somebody asking us this question. And we work with them, and we come up with ways to make it work for them and work for us. So yeah, that can help us from a fiscal year standpoint. But it's not something that Doug and I have really dialed into the model, because it's unpredictable.

Speaker 2

But we certainly have some hospitals that will help us on that front. Great. Thanks, guys. All right, great. Thank you.

Operator

Thank you. At this time, we are showing no further questioners in the queue. And this concludes our question and answer session. I would now like to turn the call back over to Steve Lisi for any closing remarks.

Speaker 2

So I'd to thank everyone for joining in. Have a great evening.

Operator

Thank you. Ladies and gentlemen, the conference of Beyond Air has now concluded. Thank you for your participation. You may now disconnect your lines.

Powered by Quartr